References
- McGee S. Muscle cramps. Arch Intern Med 1990; 150: 511–8
- Norris FH, Gasteiger EL, Chatfielf PD. An electromyographic study of induced and spontaneous cramps. Electroencephalogr Clin Neurophysiol 1957; 9: 139–47
- Riley J, Antony S. Leg cramps: differential diagnosis and management. American Family Physician 1995; 52: 1794–8
- Miller R, Moore D, Young L, Armon C, Barohn RJ, Bromberg MB, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1383–8
- Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Archives of Neurology 2003; 60: 1772–4
- Ivanhoe C, Reistetter T. Spasticity: the misunderstood part of the upper motor neuron syndrome. Am J Phys Med Rhabil 2004; 83(Suppl): S3–9
- Raynor E, Shefner J. Recurrent inhibition is decreased in patients with amyotrophic lateral sclerosis. Neurology 1994; 44: 2148–53
- Forshew D, Bromber M. A. survey of clinicians’ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 258–63
- Norris F, Sachais B, Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Archives of Neurology 1979; 36: 715–6
- De Carvalho M. Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2001; 2: 47–8
- Miller R, Moore D, Gelinas D. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–8
- Marquardt G, Lorenz R. Intrathecal baclofen for intractable spasticity in amyotrophic lateral sclerosis. Journal of Neurology 1999; 246: 619–20
- Lynch B, Lambeng N, Nocka K, Kensel P, Bajjalieh M, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861–6
- Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurons of rat hippocampal slices. Neurosci Lett. 2001; 306: 5–8
- Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18
- Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. Levetiracetam: novel modulation of ionotropic inhibitory receptors (abstract). Epilepsia 2000; 41(Suppl 7)35
- Deleu D. Levetiracetam in the treatment of idiopathic hemifacial spasm. Neurology 2004; 62: 2134–5
- Ruegg S, Stack A, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology 2004; 62: 338
- Bedlack RS, Bellanich M, Bromberg M, Cudkowicz M. Levetiracetam treatment for spasticity in motor neuron diseases: a case series. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7(Suppl 1)111
- World Federation of Neurology Research Group on Neuromuscular Diseases. 1994. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Journal of Neurological Science. 1994;124(Suppl):96–107.
- Lars D, Berg G, Hammar M, Mats H, Lasse L. The effect of oral magnesium substitution on pregnancy-induced leg cramps. Am J Obstet Gyenecol 1995; 173: 175–80
- Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. Br Med J 1995; 310: 13–7
- Stambler N, Charatran M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998; 60: 66–72
- Karsarkis, E. ALSFRS-R Validity on the Phone. Presented at the 15th Annual International Symposium on ALS/MND, Philadelphia. 2004.